Smsbiotech Inc. has gained clearance in Australia to begin a phase I trial of its small mobile stem (SMS) cell therapy for chronic obstructive pulmonary disease (COPD). BioWorld Science Regulatory ...
Smsbiotech Inc. has gained clearance in Australia to begin a phase I trial of its small mobile stem (SMS) cell therapy for chronic obstructive pulmonary disease (COPD).
One television ad claimed: "Stem cell therapy has the ability to reverse your COPD and make breathing easier for you." Older Iowans and Nebraskans were the primary targets of these fake treatments.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果